Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 384

1.

Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.

Purzner T, Purzner J, Buckstaff T, Cozza G, Gholamin S, Rusert JM, Hartl TA, Sanders J, Conley N, Ge X, Langan M, Ramaswamy V, Ellis L, Litzenburger U, Bolin S, Theruvath J, Nitta R, Qi L, Li XN, Li G, Taylor MD, Wechsler-Reya RJ, Pinna LA, Cho YJ, Fuller MT, Elias JE, Scott MP.

Sci Signal. 2018 Sep 11;11(547). pii: eaau5147. doi: 10.1126/scisignal.aau5147.

PMID:
30206138
2.

The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131.

Vilardell J, Girardi C, Marin O, Cozza G, Pinna LA, Ruzzene M.

PLoS One. 2018 Mar 1;13(3):e0193479. doi: 10.1371/journal.pone.0193479. eCollection 2018.

3.

Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival.

Vilardell J, Alcaraz E, Sarró E, Trilla E, Cuadros T, de Torres I, Plana M, Ramón Y Cajal S, Pinna LA, Ruzzene M, Morote J, Meseguer A, Itarte E.

Oncotarget. 2017 Dec 19;9(5):5736-5751. doi: 10.18632/oncotarget.23422. eCollection 2018 Jan 19.

4.

Re-evaluation of protein kinase CK2 pleiotropy: new insights provided by a phosphoproteomics analysis of CK2 knockout cells.

Franchin C, Borgo C, Cesaro L, Zaramella S, Vilardell J, Salvi M, Arrigoni G, Pinna LA.

Cell Mol Life Sci. 2018 Jun;75(11):2011-2026. doi: 10.1007/s00018-017-2705-8. Epub 2017 Nov 9.

PMID:
29119230
5.

An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2.

Jose J, Le-Borgne M, Pinna LA, Montenarh M.

Pharmaceuticals (Basel). 2017 Mar 23;10(2). pii: E33. doi: 10.3390/ph10020033.

6.

Fam20C is under the control of sphingolipid signaling in human cell lines.

Cozza G, Salvi M, Tagliabracci VS, Pinna LA.

FEBS J. 2017 Apr;284(8):1246-1257. doi: 10.1111/febs.14052. Epub 2017 Mar 22.

7.

Generation and quantitative proteomics analysis of CK2α/α'(-/-) cells.

Borgo C, Franchin C, Scalco S, Bosello-Travain V, Donella-Deana A, Arrigoni G, Salvi M, Pinna LA.

Sci Rep. 2017 Feb 17;7:42409. doi: 10.1038/srep42409.

8.

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C, Candiota AP.

Pharmaceuticals (Basel). 2017 Feb 12;10(1). pii: E24. doi: 10.3390/ph10010024.

9.

Exploring the CK2 Paradox: Restless, Dangerous, Dispensable.

Franchin C, Borgo C, Zaramella S, Cesaro L, Arrigoni G, Salvi M, Pinna LA.

Pharmaceuticals (Basel). 2017 Jan 20;10(1). pii: E11. doi: 10.3390/ph10010011. Review.

10.

From phosphoproteins to phosphoproteomes: a historical account.

Venerando A, Cesaro L, Pinna LA.

FEBS J. 2017 Jul;284(13):1936-1951. doi: 10.1111/febs.14014. Epub 2017 Feb 11. Review.

11.

Protein kinase CK2 modulates HSJ1 function through phosphorylation of the UIM2 domain.

Ottaviani D, Marin O, Arrigoni G, Franchin C, Vilardell J, Sandre M, Li W, Parfitt DA, Pinna LA, Cheetham ME, Ruzzene M.

Hum Mol Genet. 2017 Feb 1;26(3):611-623. doi: 10.1093/hmg/ddw420.

12.

New potential peptide therapeutics perturbing CK1δ/α-tubulin interaction.

Krüger M, Kalbacher H, Kastritis PL, Bischof J, Barth H, Henne-Bruns D, Vorgias C, Sarno S, Pinna LA, Knippschild U.

Cancer Lett. 2016 Jun 1;375(2):375-383. doi: 10.1016/j.canlet.2016.03.021. Epub 2016 Mar 17.

PMID:
26996302
13.

Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.

Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.

Oncotarget. 2016 Apr 5;7(14):18204-18. doi: 10.18632/oncotarget.7569.

14.

Casein kinases as potential therapeutic targets.

Cozza G, Pinna LA.

Expert Opin Ther Targets. 2016;20(3):319-40. doi: 10.1517/14728222.2016.1091883. Epub 2015 Nov 13. Review.

PMID:
26565594
15.

The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.

Cozza G, Venerando A, Sarno S, Pinna LA.

Biomed Res Int. 2015;2015:734127. doi: 10.1155/2015/734127. Epub 2015 Oct 19.

16.

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB.

Girardi C, Ottaviani D, Pinna LA, Ruzzene M.

Biomed Res Int. 2015;2015:185736. doi: 10.1155/2015/185736. Epub 2015 Oct 19.

17.

Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.

Cozza G, Zanin S, Sarno S, Costa E, Girardi C, Ribaudo G, Salvi M, Zagotto G, Ruzzene M, Pinna LA.

Biochem J. 2015 Nov 1;471(3):415-30. doi: 10.1042/BJ20141127. Epub 2015 Sep 8.

PMID:
26349539
18.

Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy.

Iori E, Ruzzene M, Zanin S, Sbrignadello S, Pinna LA, Tessari P.

Growth Factors. 2015;33(4):259-66. doi: 10.3109/08977194.2015.1073725. Epub 2015 Sep 4.

PMID:
26340273
19.

The generation of phosphoserine stretches in phosphoproteins: mechanism and significance.

Cesaro L, Pinna LA.

Mol Biosyst. 2015 Oct;11(10):2666-79. doi: 10.1039/c5mb00337g. Review.

PMID:
26211804
20.

A Single Kinase Generates the Majority of the Secreted Phosphoproteome.

Tagliabracci VS, Wiley SE, Guo X, Kinch LN, Durrant E, Wen J, Xiao J, Cui J, Nguyen KB, Engel JL, Coon JJ, Grishin N, Pinna LA, Pagliarini DJ, Dixon JE.

Cell. 2015 Jun 18;161(7):1619-32. doi: 10.1016/j.cell.2015.05.028.

21.

A Comparative Analysis and Review of lysyl Residues Affected by Posttranslational Modifications.

Cesaro L, Pinna LA, Salvi M.

Curr Genomics. 2015 Apr;16(2):128-38. doi: 10.2174/1389202916666150216221038.

22.

A new role for sphingosine: Up-regulation of Fam20C, the genuine casein kinase that phosphorylates secreted proteins.

Cozza G, Salvi M, Banerjee S, Tibaldi E, Tagliabracci VS, Dixon JE, Pinna LA.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1718-26. doi: 10.1016/j.bbapap.2015.04.023. Epub 2015 Apr 30.

PMID:
25936777
23.

Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.

Zanin S, Sandre M, Cozza G, Ottaviani D, Marin O, Pinna LA, Ruzzene M.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1694-707. doi: 10.1016/j.bbapap.2015.04.026. Epub 2015 Apr 30.

PMID:
25936516
24.

Protein kinase CK2 potentiates translation efficiency by phosphorylating eIF3j at Ser127.

Borgo C, Franchin C, Salizzato V, Cesaro L, Arrigoni G, Matricardi L, Pinna LA, Donella-Deana A.

Biochim Biophys Acta. 2015 Jul;1853(7):1693-701. doi: 10.1016/j.bbamcr.2015.04.004. Epub 2015 Apr 15.

25.

Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.

Franchin C, Salvi M, Arrigoni G, Pinna LA.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1676-86. doi: 10.1016/j.bbapap.2015.04.002. Epub 2015 Apr 14.

PMID:
25882195
26.

Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization.

Herhaus L, Perez-Oliva AB, Cozza G, Gourlay R, Weidlich S, Campbell DG, Pinna LA, Sapkota GP.

Sci Signal. 2015 Apr 14;8(372):ra35. doi: 10.1126/scisignal.aaa0441.

27.

Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients.

Richter J, Ullah K, Xu P, Alscher V, Blatz A, Peifer C, Halekotte J, Leban J, Vitt D, Holzmann K, Bakulev V, Pinna LA, Henne-Bruns D, Hillenbrand A, Kornmann M, Leithäuser F, Bischof J, Knippschild U.

Int J Cancer. 2015 Jun 15;136(12):2799-810. doi: 10.1002/ijc.29346. Epub 2014 Dec 1. Erratum in: Int J Cancer. 2016 Aug 15;139(4):E5.

28.

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.

De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, Salvadori L, Grassia R, Leone CA, De Rosa G, Maiuri MC, Pettoello-Mantovani M, Guido S, Bossi A, Zolin A, Venerando A, Pinna LA, Mehta A, Bona G, Kroemer G, Maiuri L, Raia V.

Autophagy. 2014;10(11):2053-74. doi: 10.4161/15548627.2014.973737.

29.

Identification of the PLK2-dependent phosphopeptidome by quantitative proteomics [corrected].

Franchin C, Cesaro L, Pinna LA, Arrigoni G, Salvi M.

PLoS One. 2014 Oct 22;9(10):e111018. doi: 10.1371/journal.pone.0111018. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e114202.

30.

Casein kinase: the triple meaning of a misnomer.

Venerando A, Ruzzene M, Pinna LA.

Biochem J. 2014 Jun 1;460(2):141-56. doi: 10.1042/BJ20140178. Review.

PMID:
24825444
31.

Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions.

Girardi C, James P, Zanin S, Pinna LA, Ruzzene M.

Biochim Biophys Acta. 2014 Sep;1843(9):1865-74. doi: 10.1016/j.bbamcr.2014.04.020. Epub 2014 Apr 24.

32.

Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2).

Cozza G, Zanin S, Determann R, Ruzzene M, Kunick C, Pinna LA.

PLoS One. 2014 Feb 24;9(2):e89176. doi: 10.1371/journal.pone.0089176. eCollection 2014.

33.

A "SYDE" effect of hierarchical phosphorylation: possible relevance to the cystic fibrosis basic defect.

Venerando A, Cesaro L, Marin O, Donella-Deana A, Pinna LA.

Cell Mol Life Sci. 2014 Jun;71(12):2193-6. doi: 10.1007/s00018-014-1581-8. Epub 2014 Feb 25.

PMID:
24566881
34.

The lysine-specific demethylase 1 is a novel substrate of protein kinase CK2.

Costa R, Arrigoni G, Cozza G, Lolli G, Battistutta R, Izpisua Belmonte JC, Pinna LA, Sarno S.

Biochim Biophys Acta. 2014 Apr;1844(4):722-9. doi: 10.1016/j.bbapap.2014.01.014. Epub 2014 Jan 31.

PMID:
24486797
35.

Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.

Cozza G, Girardi C, Ranchio A, Lolli G, Sarno S, Orzeszko A, Kazimierczuk Z, Battistutta R, Ruzzene M, Pinna LA.

Cell Mol Life Sci. 2014 Aug;71(16):3173-85. doi: 10.1007/s00018-013-1552-5. Epub 2014 Jan 18.

PMID:
24442476
36.

CK2 involvement in ESCRT-III complex phosphorylation.

Salvi M, Raiborg C, Hanson PI, Campsteijn C, Stenmark H, Pinna LA.

Arch Biochem Biophys. 2014 Mar 1;545:83-91. doi: 10.1016/j.abb.2014.01.006. Epub 2014 Jan 15.

PMID:
24440309
37.

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.

J Hematol Oncol. 2013 Oct 12;6:78. doi: 10.1186/1756-8722-6-78.

38.

Phosphorylation of cystic fibrosis transmembrane conductance regulator (CFTR) serine-511 by the combined action of tyrosine kinases and CK2: the implication of tyrosine-512 and phenylalanine-508.

Cesaro L, Marin O, Venerando A, Donella-Deana A, Pinna LA.

Amino Acids. 2013 Dec;45(6):1423-9. doi: 10.1007/s00726-013-1613-y. Epub 2013 Nov 1.

PMID:
24178769
39.

Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation.

Venerando A, Franchin C, Cant N, Cozza G, Pagano MA, Tosoni K, Al-Zahrani A, Arrigoni G, Ford RC, Mehta A, Pinna LA.

PLoS One. 2013 Sep 18;8(9):e74232. doi: 10.1371/journal.pone.0074232. eCollection 2013.

40.

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.

Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22.

41.

Response to Wang et al.: Secreted protein kinases?

Tagliabracci VS, Pinna LA, Dixon JE.

Trends Biochem Sci. 2013 Sep;38(9):425. doi: 10.1016/j.tibs.2013.06.007. No abstract available.

PMID:
23992948
42.

CK1δ kinase activity is modulated by Chk1-mediated phosphorylation.

Bischof J, Randoll SJ, Süßner N, Henne-Bruns D, Pinna LA, Knippschild U.

PLoS One. 2013 Jul 4;8(7):e68803. doi: 10.1371/journal.pone.0068803. Print 2013.

43.

Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation.

Venerando A, Girardi C, Ruzzene M, Pinna LA.

Biochem J. 2013 May 15;452(1):131-7. doi: 10.1042/BJ20121140.

PMID:
23438105
44.

Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.

Cozza G, Sarno S, Ruzzene M, Girardi C, Orzeszko A, Kazimierczuk Z, Zagotto G, Bonaiuto E, Di Paolo ML, Pinna LA.

Biochim Biophys Acta. 2013 Jul;1834(7):1402-9. doi: 10.1016/j.bbapap.2013.01.018. Epub 2013 Jan 27.

PMID:
23360763
45.

Secreted protein kinases.

Tagliabracci VS, Pinna LA, Dixon JE.

Trends Biochem Sci. 2013 Mar;38(3):121-30. doi: 10.1016/j.tibs.2012.11.008. Epub 2012 Dec 29. Review.

46.

Kinase CK2 inhibition: an update.

Cozza G, Pinna LA, Moro S.

Curr Med Chem. 2013;20(5):671-93. Review.

PMID:
23210774
47.

Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Zanin S, Borgo C, Girardi C, O'Brien SE, Miyata Y, Pinna LA, Donella-Deana A, Ruzzene M.

PLoS One. 2012;7(11):e49193. doi: 10.1371/journal.pone.0049193. Epub 2012 Nov 8.

48.

CFTR mutations altering CFTR fragmentation.

Tosoni K, Stobbart M, Cassidy DM, Venerando A, Pagano MA, Luz S, Amaral MD, Kunzelmann K, Pinna LA, Farinha CM, Mehta A.

Biochem J. 2013 Jan 1;449(1):295-305. doi: 10.1042/BJ20121240.

49.

Protein kinase CK2 inhibitors: a patent review.

Cozza G, Pinna LA, Moro S.

Expert Opin Ther Pat. 2012 Sep;22(9):1081-97. doi: 10.1517/13543776.2012.717615. Review.

PMID:
22908959
50.

Investigation on PLK2 and PLK3 substrate recognition.

Salvi M, Trashi E, Cozza G, Franchin C, Arrigoni G, Pinna LA.

Biochim Biophys Acta. 2012 Dec;1824(12):1366-73. doi: 10.1016/j.bbapap.2012.07.003. Epub 2012 Jul 21.

PMID:
22828320

Supplemental Content

Loading ...
Support Center